Publications by the researcher in collaboration with Pablo Luis Ortiz Romero (16)

2023

  1. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64

  2. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

    Actas Dermo-Sifiliograficas

  3. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298

2022

  1. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial

    The Lancet Haematology, Vol. 9, Núm. 6, pp. e425-e433

  2. EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: Real-world data in Spanish patients (MICADOS Study)

    JEADV Clinical Practice, Vol. 1, Núm. 4, pp. 438-449

2021

  1. EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: real-world data in Spanish patients (MICADOS study)

    European Journal of Cancer, Vol. 156, pp. S29-S30

  2. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the European Academy of Dermatology and Venereology

2020

  1. Cost of early-stage mycosis fungoides treatments in Spain

    ClinicoEconomics and Outcomes Research, Vol. 12, pp. 91-105

  2. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma

    Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 4, pp. 762-768

  3. Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 5, pp. 1535-1538

2018

  1. Association of APOA5 and APOC3 Genetic Polymorphisms with Severity of Hypertriglyceridemia in Patients with Cutaneous T-Cell Lymphoma Treated with Bexarotene

    JAMA Dermatology, Vol. 154, Núm. 12, pp. 1424-1431

  2. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study

    Clinical and Experimental Dermatology, Vol. 43, Núm. 2, pp. 137-143

  3. The First Year of the AEVD Primary Cutaneous Lymphoma Registry

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 610-616

2013

  1. Erratum: MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma (Modern Pathology (2012) DOI; 10.1038/modpathol.2012.149)

    Modern Pathology

  2. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

    Modern Pathology, Vol. 26, Núm. 2, pp. 171-181

2012

  1. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: An epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma

    British Journal of Dermatology, Vol. 167, Núm. 1, pp. 174-179